Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
Multimodal Analgesia Pathway Assessing Role of Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery
Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters. This prospective open-label interventional single-center study will compare 30-day postoperative patient reported outcomes and pain medication use between a pre-implementation cohort of patients managed with standard-of-care multimodal analgesia after ureteroscopy with a post-implementation cohort of patient with this regimen and addition of suzetrigine. The primary outcome will be opioid usage after discharge with standard of care multimodal analgesia (historical control) vs opioid usage after discharge with suzetrigine included with the standard of care
multimodal analgesia regimen (intervention). Secondary outcomes will include unplanned care encounters within 30 days (Emergency Room, unplanned clinic visits) and surveyed patient reported outcomes measured on a post-operative survey including PROMIS (Patient-Reported Outcomes Measurement Information System) questions as well as an end of study administration of WISQOL (The Wisconsin Stone Quality of Life Questionnaire). The study will be conducted within a single academic institution including the primary hospital (Brigham and Women's Hospital) and satellite sites (Brigham and Women's Faulkner Hospital).
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Daniel A Wollin, MD, MS
- Número de teléfono: 617 732 6354
- Correo electrónico: dwollin@mgb.org
Copia de seguridad de contactos de estudio
- Nombre: Christopher Magnani, MD, MS, MPhil
- Correo electrónico: CMAGNANI@BWH.HARVARD.EDU
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Brigham and Women's Hospital
-
Contacto:
- Daniel A Wollin, MD, MS
- Número de teléfono: 617 732 6354
- Correo electrónico: dwollin@mgb.org
-
Boston, Massachusetts, Estados Unidos, 02130
- Reclutamiento
- Brigham and Women's Faulkner Hospital
-
Contacto:
- Daniel A Wollin, MD, MS
- Número de teléfono: 617 732 6354
- Correo electrónico: dwollin@mgb.org
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients undergoing ureteroscopy between ages 21 to 80 at BWFH (Brigham & Women's Faulkner Hospital) by one of the department's high volume endoscopic surgeons. Patient who are or not pre-stented prior to surgery will be included (these will be assessed via stratification within a secondary analysis).
- Patients able to consent for their own medical care (i.e. consent able to be obtained directly from patient and does not require a healthcare proxy or guardian)
Exclusion Criteria:
- Regular opioid use prior to surgery or significant substance abuse concerns.
- Inability of patient to provide their own consent (i.e. lack capacity).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: multimodal analgesia pathway (standard, no suzetrigine)
multimodal analgesia pathway without suzetrigine |
multimodal analgesia regimen |
|
Experimental: suzetrigine with multimodal analgesia pathway
addition of suzetrigine to multimodal analgesia pathway |
suzetrigine with multimodal analgesia regimen |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Post-discharge opioid consumption (MME)
Periodo de tiempo: 1-2 weeks
|
assessed at post-operative visit |
1-2 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Post-discharge opioid consumption (MME)
Periodo de tiempo: 30 days
|
assessed at 30 days after surgery |
30 days
|
|
Rate of unplanned care encounters
Periodo de tiempo: 30 days
|
Emergency Room visits |
30 days
|
|
patient reported outcomes: pain score
Periodo de tiempo: 2 weeks
|
measured on a 0 to 10 analog scale on post-operative survey |
2 weeks
|
|
patient reported outcomes: pain score
Periodo de tiempo: 30 days
|
measured on a 0 to 10 analog scale on post-operative survey |
30 days
|
|
patient reported outcomes: PROMIS composite score
Periodo de tiempo: 2 weeks
|
total score where each of the following is rated from 0 to 4 then aggregated into a total value:
|
2 weeks
|
|
patient reported outcomes: PROMIS composite score
Periodo de tiempo: 30 days
|
total score where each of the following is rated from 0 to 4 then aggregated into a total value:
|
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with your day-to-day activities
Periodo de tiempo: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with your day-to-day activities
Periodo de tiempo: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with work around the home
Periodo de tiempo: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with work around the home
Periodo de tiempo: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with your ability to participate in social activities
Periodo de tiempo: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with your ability to participate in social activities
Periodo de tiempo: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with your household chores
Periodo de tiempo: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with your household chores
Periodo de tiempo: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with things you usually do for fun
Periodo de tiempo: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with things you usually do for fun
Periodo de tiempo: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with your enjoyment of social activities
Periodo de tiempo: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with your enjoyment of social activities
Periodo de tiempo: 30 days
|
rated from 0 to 4 |
30 days
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2026P000126
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
This trial is being performed at within a single institution (Mass General Brigham) at two of it's constituent sites (BWH and BWFH), as part of IRB approval of the study decision was for privacy policy that only aggregated data would be intended to be shared outside the institutions system and any IPD would be solely stored on HIPAA compliant servers at the facility. De-identified or aggregated data would be permitted to be shared so long as subjects could not be identified.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .